603456.CG▲
Zhongji Innolight repurchases over 300 million yuan on first day; multiple A-share companies disclose buyback progress
Several A-share companies disclosed progress on share buybacks. Among them, Zhongji Innolight repurchased 374,100 shares on the first day after announcing a planned buyback of up to 8 billion yuan, paying a total of 318 million yuan. As of August 31, China Petroleum and Chemical Corporation had cumulatively repurchased 104 million A-shares for a total of 500 million yuan; Jiuzhou Pharmaceutical had repurchased 15.41 million shares for 212 million yuan; MGI Tech had repurchased 2.01 million shares for about 100 million yuan; Double Medical Technology had repurchased 6.21 million shares for 260 million yuan; Jiansheng Group had repurchased 19.25 million shares for 224 million yuan; and Bear Electric Appliance had repurchased 1.95 million shares for 65.95 million yuan.
603456.CG▼
Jiuzhou Pharmaceutical Reports First-Half Revenue and Profit Declines, Heavy Reliance on Single Customer Persists
Zhejiang Jiuzhou Pharmaceutical has disclosed its financial results for the first half of 2026. Operating revenue reached 2.575 billion yuan, down 10.30 percent year-on-year, while net profit attributable to shareholders fell 26.33 percent to 387 million yuan. Net cash flow from operating activities was 553 million yuan, a decrease of 34.52 percent, mainly due to lower receipts from sales. Among accounts receivable, the single largest customer accounted for 736 million yuan at period-end, representing 65.22 percent of the combined total of accounts receivable and contract assets. The top five customers together made up 72.29 percent, highlighting the company's continued heavy dependence on one major client. Overseas markets contributed 79.53 percent of first-half revenue, but revenue from those markets declined 10.72 percent year-on-year. Financial expenses surged 315.17 percent to 16 million yuan because of foreign exchange losses. Revenue from the CDMO business was 1.973 billion yuan, accounting for 76.62 percent of total operating revenue, underscoring an equally pronounced reliance on a single business line. Among comparable listed companies, Jiuzhou Pharmaceutical's revenue has barely grown over the past four years, coming in at 5.445 billion yuan in 2022, 5.523 billion yuan in 2023, 5.161 billion yuan in 2024, and 5.509 billion yuan in 2025. Net profit attributable to shareholders peaked at 1.033 billion yuan in 2023 before retreating. The company is advancing a key customer strategy and building a specialty process platform, but collection efficiency dropped sharply in the first half. The choice between protecting earnings or protecting customers may become clear in the second half.
603456.CG▼
Jiuzhou Pharmaceutical's 2026 interim net profit at 387 million yuan, down 26.33% year-on-year
Jiuzhou Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company at 387 million yuan, a decrease of 26.33% compared to the same period last year. Total operating revenue was 2.575 billion yuan, down 10.30% year-on-year. Net cash flow from operating activities was 553 million yuan, down 34.52% year-on-year. The latest asset-liability ratio stands at 15.76%, gross margin at 36.89%, ROE at 4.35%, and diluted earnings per share at 0.44 yuan.
603456.CG▲
Nearly 100 Shanghai-listed companies unveil intensive positive signals, with buybacks, stake increases, and interim dividends in full swing
This evening, nearly 100 companies listed on the Shanghai Stock Exchange released a flurry of positive signals, spanning share buybacks and stake increases, improving business performance, proposed selections in centralized drug procurement, and interim dividend returns. On the buyback and stake increase front, two new buyback plans were added by Bethel Automotive Safety Systems and Shandong Hi-Speed, with a combined proposed buyback cap of 400 million yuan. Soochow Securities disclosed a controlling shareholder's stake increase plan, with a proposed increase amount not exceeding 200 million yuan, while another 76 companies simultaneously disclosed progress updates on buybacks and stake increases. At the operational level, results of the 12th round of national centralized drug procurement were gradually announced, with multiple Shanghai-listed pharmaceutical companies including Harbin Pharmaceutical Group, Zhejiang Huahai Pharmaceutical, China Resources Double-Crane Pharmaceutical, North China Pharmaceutical, Jiangsu Lianhuan Pharmaceutical, Aurisco Pharmaceutical, and Jianfeng Group declaring that their products have been proposed for selection. In terms of investor returns, four companies—WuXi AppTec, Zhejiang Jiuzhou Pharmaceutical, Kingfa Sci. & Tech., and Jasan Group—unveiled interim dividend plans on the same day. Among them, WuXi AppTec plans to distribute a cash dividend of 5.1 yuan per 10 shares, with the total interim dividend expected to exceed 1.5 billion yuan. Additionally, the controlling shareholder of Lujiazui voluntarily committed not to transfer or reduce its holdings in any way within the next 12 months, coinciding with the unlocking of restricted shares from the company's private placement.
603456.CG
Jiuzhou Pharmaceutical Completes Industrial and Commercial Registration Change, Registered Capital Adjusted to 881.710028 Million Yuan
Jiuzhou Pharmaceutical recently completed the industrial and commercial registration change procedures and obtained a renewed Business License issued by the Zhejiang Provincial Administration for Market Regulation. The registered capital has been changed to 881.710028 million yuan. The company's legal representative remains Hua Lirong, and its business scope covers the research and development, production, and sales of chemical active pharmaceutical ingredients, pharmaceutical intermediates, and pharmaceutical preparations.
China